Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1141965

	registered interest
	date	25/07/2019
	answering body	Department for Environment, Food and Rural Affairs
	answering dept id	13
	answering dept short name	Environment, Food and Rural Affairs
	answering dept sort name	Environment, Food and Rural Affairs
	hansard heading	Rivers: Sewage
	house id	1
	legislature	25259 pref label House of Commons
	question text	What recent assessment he has made of the effect of sewage discharges on water quality in rivers.
	tabling member constituency	Keighley
	tabling member printed	John Grogan
	uin	912191
	answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>Last year, the Environment Agency (EA) reported that there had been good progress in meeting water quality targets. Since 1995, investment in sewage treatment has achieved a 61% reduction in the amount of phosphorus and a 72% reduction in the amount of ammonia discharged to rivers. We will continue to work with the water companies.</p> answering member constituency Suffolk Coastal answering member printed Dr Thérèse Coffey question first answered 25/07/2019 16:19:47 answering member 4098 label Biography information for Dr Thérèse Coffey
	tabling member	382 label Biography information for John Grogan

1141968

	registered interest
	date	25/07/2019
	answering body	Department for Environment, Food and Rural Affairs
	answering dept id	13
	answering dept short name	Environment, Food and Rural Affairs
	answering dept sort name	Environment, Food and Rural Affairs
	hansard heading	Animal Products: Import Controls
	house id	1
	legislature	25259 pref label House of Commons
	question text	What steps he is taking to ban products of trophy hunting from being imported to the UK.
	tabling member constituency	Mid Derbyshire
	tabling member printed	Mrs Pauline Latham
	uin	912196
	answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>We must proceed on the basis of evidence. We will publish a Call for Evidence on the impact of international trade in hunting trophies between the UK and other countries, to understand whether further action is needed to address impacts on the species, and the profound ethical concerns involved.</p> answering member constituency Suffolk Coastal answering member printed Dr Thérèse Coffey question first answered 25/07/2019 15:57:25 answering member 4098 label Biography information for Dr Thérèse Coffey
	tabling member	4025 label Biography information for Mrs Pauline Latham

1141957

	registered interest
	date	24/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Breast Cancer: Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what are the drugs approved by NICE to treat HER2+ breast cancer; and what assessment they have made of the efficacy of such drugs.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL17501
	answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for making recommendations for the National Health Service on whether drugs and other treatments represent a clinically and cost effective use of NHS resources.</p><p>NICE has recommended the following drugs for the treatment of HER2-positive breast cancer: trastuzumab emtansine (Kadcyla) for treating HER2-positive advanced breast cancer after trastuzumab (Herceptin) and a taxane; pertuzumab (Perjeta) with trastuzumab (Herceptin) and docetaxel for treating HER2-positive breast cancer; pertuzumab (Perjeta) for the neoadjuvant treatment of HER2-positive breast cancer; and pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer.</p><p>NHS commissioners are legally required to fund drugs recommended in NICE technology appraisal guidance. It is for clinicians to decide on the most appropriate treatment for an individual patient based on their clinical judgement and in discussion with the patient.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL17502 question first answered 25/07/2019 16:45:03 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

1141958

	registered interest
	date	24/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pertuzumab
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what advice they provide to clinicians for the use of Pertuzumab rather than Herceptin for the treatment of HER2+ breast cancer.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL17502
	answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for making recommendations for the National Health Service on whether drugs and other treatments represent a clinically and cost effective use of NHS resources.</p><p>NICE has recommended the following drugs for the treatment of HER2-positive breast cancer: trastuzumab emtansine (Kadcyla) for treating HER2-positive advanced breast cancer after trastuzumab (Herceptin) and a taxane; pertuzumab (Perjeta) with trastuzumab (Herceptin) and docetaxel for treating HER2-positive breast cancer; pertuzumab (Perjeta) for the neoadjuvant treatment of HER2-positive breast cancer; and pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer.</p><p>NHS commissioners are legally required to fund drugs recommended in NICE technology appraisal guidance. It is for clinicians to decide on the most appropriate treatment for an individual patient based on their clinical judgement and in discussion with the patient.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL17501 question first answered 25/07/2019 16:45:03 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

1141255

	registered interest
	date	23/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Non-surgical Cosmetic Procedures: Children
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what legal duties govern the administering of dermal fillers to people under the age of 18 by non-regulated practitioners.
	tabling member constituency	North Durham
	tabling member printed	Mr Kevan Jones
	uin	280927
	answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>Currently there are no restrictions that limit the administration of dermal fillers on young people under the age of 18 years old.</p><p>The Department is exploring options to introduce age restrictions on access to cosmetic procedures, bringing them in line with legislation on tattoos, teeth whitening and the use of sunbeds. From May 2020 all dermal fillers, irrespective of their composition and intended use, will be regulated as medical devices under Annex XVI of the Medical Device Regulations (EU 2017/745). The new Regulations will significantly improve the quality and safety of dermal fillers.</p><p>The Government is committed to improving the safety of cosmetic procedures through better training for practitioners, and clear information so that people can make informed decisions about their care. The growth in non-surgical treatments increases the need for consumer protection and we are currently working with stakeholders to strengthen the regulation of cosmetic procedures.</p><p>We urge anyone seeking a cosmetic procedure to take the time to find a reputable, insured and appropriately qualified practitioner who is either subject to statutory regulation or on a voluntary register accredited by the Professional Standards Authority.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 25/07/2019 16:32:36 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	1438 label Biography information for Mr Kevan Jones

1141380

	registered interest
	date	23/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	MMR Vaccine: Safety
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to maintain and improve pharmacovigilance in relation to the MMR vaccine.
	tabling member constituency	Gravesham
	tabling member printed	Adam Holloway
	uin	280998
	answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>As with all vaccines and medicines, the safety of the Measles, Mumps and Rubella (MMR) vaccine remains under continual review by the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA uses all available sources of evidence in pharmacovigilance, including regular review of suspected adverse reactions submitted through the Yellow Card Scheme, data from clinical and epidemiological studies, the medical literature and information from pharmaceutical companies and other worldwide regulatory authorities. The MHRA’s processes and data analysis systems are regularly evaluated to ensure optimal performance in monitoring the safety of vaccines and medicines.</p><p>The balance of benefits and risks of MMR vaccine remains overwhelmingly favourable.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 25/07/2019 16:35:38 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	1522 label Biography information for Adam Holloway

1141381

	registered interest
	date	23/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	MMR Vaccine
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to help ensure (a) transparency and (b) accountability in the process of manufacturing the MMR vaccine.
	tabling member constituency	Gravesham
	tabling member printed	Adam Holloway
	uin	280999
	answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>Two Measles, Mumps and Rubella (MMR) vaccines are licensed for use in the United Kingdom: M-M-RVaxPro and Priorix. Both vaccines are on the National Health Service’s routine immunisation schedule. The quality, safety and efficacy of both M-M-RVaxPro and Priorix have been evaluated before they were given a Marketing Authorisation in Europe, and the Marketing Authorisation Holder for each vaccines is legally required to submit periodic safety update reports to the regulator, which are documents intended to provide an evaluation of the risk-benefit balance of a medicinal product at defined time points after its authorisation. The sites at which the products are manufactured are also required to undergo periodic inspections to ensure that they comply with Good Manufacturing Practices. Each batch of vaccines is tested by an official medicines control laboratory (OMCL). OMCL testing is independent of and in addition to the manufacturer’s testing. These procedures ensure that the MMR vaccines available in the UK are safe and efficacious and that the manufacturers/Marketing Authorisation holders are held accountable for their products.</p><p>A European Public Assessment Report (EPAR) for M-M-RVaxPro is available at the following link:</p><p><a href="https://www.ema.europa.eu/en/documents/scientific-discussion/m-m-rvaxpro-epar-scientific-discussion_en.pdf" target="_blank">https://www.ema.europa.eu/en/documents/scientific-discussion/m-m-rvaxpro-epar-scientific-discussion_en.pdf</a></p><p>Priorix was approved before public assessment reports were a requirement. The EPAR for M-M-RVaxPro contains a general summary of the manufacturing information that was provided during the assessment process; however, the specific details of the manufacturing process are confidential.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 25/07/2019 16:38:57 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	1522 label Biography information for Adam Holloway

1140803

	registered interest
	date	22/07/2019
	answering body	Church Commissioners
	answering dept id	9
	answering dept short name	Church Commissioners
	answering dept sort name	Church Commissioners
	hansard heading	Churches: Grants
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the right hon. Member for Meriden, representing the Church Commissioners, what steps are being taken to promote the new four year Grant Programme through the Churches Trust.
	tabling member constituency	East Londonderry
	tabling member printed	Mr Gregory Campbell
	uin	280172
	answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>The Church of England’s Church Buildings Council regularly communicates with all grant-making bodies and information about the grants available to parishes is communicated through the Diocesan Advisory Committees.</p><p>The Church of England offers general advice to its parishes about restoration, repair and grants on the Church Care section of its website: <a href="https://www.churchofengland.org/more/church-resources/churchcare" target="_blank">https://www.churchofengland.org/more/church-resources/churchcare</a></p> answering member constituency Meriden answering member printed Dame Caroline Spelman question first answered 25/07/2019 16:24:32 answering member 312 label Biography information for Dame Caroline Spelman
	tabling member	1409 label Biography information for Mr Gregory Campbell

1140806

	registered interest
	date	22/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Public Health: Disadvantaged
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of reductions in public health funding on health inequalities.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	280246
	answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>Public health services can have a significant impact in improving the health of the population and reducing unfair differences between marginalised groups of people or communities.</p><p>The Government has made difficult choices to protect public services in the long term. We remain committed to securing five extra years of healthy, independent life by 2035 and reducing the gap between rich and poor with proposals set out in the Prevention Green Paper and a Long Term Plan for the National Health Service with a greater focus on prevention. We want everyone to have the same opportunity to have a long healthy life, whoever they are and whatever their social circumstances.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 280247 question first answered 25/07/2019 16:09:54 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	4131 label Biography information for Jim Shannon

1140807

	registered interest
	date	22/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Public Health: Disadvantaged
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of reductions in public health funding on the health and wellbeing of the most marginalised people in the UK.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	280247
	answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>Public health services can have a significant impact in improving the health of the population and reducing unfair differences between marginalised groups of people or communities.</p><p>The Government has made difficult choices to protect public services in the long term. We remain committed to securing five extra years of healthy, independent life by 2035 and reducing the gap between rich and poor with proposals set out in the Prevention Green Paper and a Long Term Plan for the National Health Service with a greater focus on prevention. We want everyone to have the same opportunity to have a long healthy life, whoever they are and whatever their social circumstances.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 280246 question first answered 25/07/2019 16:09:54 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	4131 label Biography information for Jim Shannon